Non-interventional Study With Ectoin Containing and/or Decongesting Nasal Spray in Patients With Rhinosinusitis

• Physicians' assessment of general well-being of patients[ Time Frame: day 0 and day 7 and day 14 (if necessary, depending on study duration) ]
  The investigators will assess the well-being of patients using a 4-point scale (good condition to strong illness).
• Patients' assessment of intensity of symptoms and their influence on quality of life[ Time Frame: 7 to 14 days (depending on study duration) ]
  Patients will document their rhinosinusitis symptoms and their influence on quality of life (22 parameters in accordance with the "sino-nasal outcome test-22 questionnaire") and the additional symptom "dry nose". They will document their judgement daily in a patient diary using a 6-point scale (0=no problem to 5=as bad as possible).
• Assessment of the efficacy of treatments[ Time Frame: once on day 7 or day 14 (depending on study duration) ]
  At the end of the study, both investigators and patients will judge the overall efficacy of the treatment based on a 6-point scale (1=very good to 6=unsatisfactory).
• Assessment of the tolerability of treatments[ Time Frame: once on day 7 or day 14 (depending on study duration) ]
  Both investigators and patients will judge the tolerability of the treatments at the end of the study. Both investigators and patients will judge the tolerability based on a 6 point scale (1=very good to 6 = unsatisfactory).
• Incidence of adverse events/serious adverse events[ Time Frame: 7 to 14 days (depending on study duration) ]
  All occurring adverse events/serious adverse events will be documented during the entire study period.

The goal of this non-interventional study is to investigate the efficacy and tolerability of an Ectoin containing Rhinosinusitis Nasal Spray (SNS01). Within the study, SNS01 will be used either alone as monotherapy or as concomitant therapy in addition to the use of a Xylometazoline-containing decongestant nasal spray. A control group will use a Xylometazoline-containing decongestant nasal spray as monotherapy. It will be investigated if the dose of the used decongestant nasal spray might be reduced, the development of the disease might be positively influenced and/or the potentially occurring side effects (e.g. dryness of the nasal mucosa, sneezing) might be alleviated by using the Ectoin containing Rhinosinusitis Nasal Spray as concomitant therapy.

• Drug: Xylometazoline Nasal Spray
  Application of Xylometazoline Nasal Spray in accordance with the instructions for use
• Device: Ectoin Rhinosinusitis Nasal Spray
  Application of Ectoin Nasal Spray (SNS01) in accordance with the instructions for use

• : Ectoin Rhinosinusitis Nasal Spray
  application of 1-2 sprays of SNS01 into each nostril several times a day
• : Xylometazoline nasal spray
  1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
• : Xylometazoline + Ectoin Nasal Spray
  Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Spray (SNS01): 1-2 sprays per nostril several times a day